Na Cocer Peptides bin rayt am 
1 mɔnt dɔn pas
ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.
Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.
1 Ɔvaviu
Tayp 2 dayabitis (T2D) na wan kכmכn krεse mεtabolik dizכrd wae de kכl insulin rεsistεns εn nכ insulin sekreshכn, we de mek di blɔd glukכs lεvεl go כp. Wit di global rise in obisiti rεt, di insidεns fכ T2D de kכntinyu fכ inkrεs. di wet mεnejmεnt na impɔtant tin fɔ trit T2D, bikɔs bɔku tɛm if pɔsin fat kin mek di insulin rεsistεns wɔs ɛn i kin mek i nɔ ebul fɔ kɔntrol di glukɔs na di blɔd mɔ. Fɔ divɛlɔp drɔgs we go ebul fɔ rigul di blɔd glukɔs lɛvɛl fayn fayn wan we i de ɛp fɔ mɛn yu wet dɔn bi wan risach we dɛn de pe atɛnshɔn pan na di fild fɔ T2D tritmɛnt. Cagrilintide, as wan nyu drɔg, dɔn mek pipul dɛn pe atɛnshɔn mɔ ɛn mɔ.
Figure 1 Di dayabεtis- εn obesity-rεlatεd ifekt dεm fכ GLP-1.
2 Di Rol we Kagrilintayd de ple fɔ mek di blɔd glukɔs rigyuleshɔn
Rigyuletɔri Mɛkanism
kagrilintayd na glukagon lεk pεptida-1 (GLP-1) analכg. GLP-1 na inkrεtin כmon we de ple imכtant rol fכ rεgεl di glukכs na di bכdi. afta dεn it, di intestinal εndokrin sεl dεm de sekret GLP-1, we de mek insulin sekreshכn insay wan we we dipεnd pan glukכs kכnsantreshכn, we de mek di blכd glukכs lεvεl dכn. Cagrilintide gεt hכy afiniti fכ GLP-1 rεsεpכta dεm εn i kin miks di fysiolojikal ifekt dεm fכ GLP-1. we di blכd glukכs lεvεl go כp, Cagrilintide de biεn di GLP-1 rεsεpכta, we de aktibכt wan siriכs intasεlulyar signal path dεm we de protεkt insulin sεntesis εn rilis, we de mek glukכs ebul fכ go insay sεl dεm fכ yutilizeshכn εn dat de mek di bכdi glukכs kכnsantreshכn dכn. i de inhibit glukagon sekreshכn bak εn i de ridyus di hεpatik glukכs autput, we de mek di blכd glukכs lεvεl mכr stεbyul.
Klinik ɛfifikɛshɔn
Bɔku klinik stɔdi dɛn dɔn sho se Cagrilintide de sho fayn fayn blɔd glukɔs rɛgyuleshɔn ifɛkt pan pasɛnt dɛn we gɛt tayp 2 dayabitis. Insay wan randomized, double-blind, placebo-controlled klinik trial, dɛn bin sheb T2D pasɛnt dɛn to wan Cagrilintide tritmɛnt grup ɛn wan plasɛbo grup. Afta 12 wiks we dɛn tek di tritmɛnt, dɛn bin si se di pasɛnt dɛn we de na di Cagrilintide tritmɛnt grup bin gɛt signifyant dɛkɛshɔn pan di ɛmoglobin A1c (HbA1c) lɛvɛl we dɛn kɔmpia am wit di beslayn, wit notabɛl ridɔkshɔn pan fast blɔd glukɔs ɛn postprandial blɔd glukɔs lɛvɛl. HbA1c na imכtant indikεtכ fכ lכng tεm blכd glukכs kכntrכl, εn di dכn we i dכn de sho se Cagrilintide kin ifektiv εn sustainably impruv di pasεnshכn in blɔd glukכs kכntrכl. We yu kɔmpia am wit tradishɔnal antidiabetic drɔgs, Cagrilintide de ridyus di blɔd glukɔs lɛvɛl we i de mek i nɔ gɛt bɛtɛ blɔd risk. dis kin bi fכ in glukכs kכnsantreshכn-dipεndεnt insulin sekreshכn-prכmot mεkanism, we min se i de כnli stimulat insulin sekreshכn we di blכd glukכs lεvεl go כp εn i nכ de lכs pasmak blכd glukכs lεvεl we i nכmal.
3 Mεkanism fכ Akshכn fכ Kagrilintayd in Wεyt Mεnejmεnt
Cagrilintide de ridyus di it we yu de it bay we i de stɔp di apɛtit. i de akt pan di sεntri nεv sεstem, we de infכlכw di satiety sεnta na di haypothalamus fכ mek i fil fכ fulכp, we de mek i rεdכks fכ it. di kagrilintayd kin mek di bɛlɛ ɛmti, i kin mek di it we de na di bɛlɛ lɔng lɔng, i kin mek pɔsin satis mɔ, ɛn i kin mek i nɔ it di it we i kin it afta dat. i kin infכlכw di fεt mεtabolism bak bay we i de mek di fεt כksidεshכn εn i de inkrεs di εnεji we i de spεnd, we de εp fכ lכs di wet.
4 Aplikeshɔn fɔ Kagrilintayd fɔ Trit Tayp 2 Dayabitis
Indikashɔn dɛn
Cagrilintide fayn fɔ bɔku pan di wan dɛn we gɛt tayp 2 dayabitis, mɔ di wan dɛn we gɛt bɔku bɔku bɔdi ɔ we fat pasmak. Fɔ di pasɛnt dɛn we nɔ gɛt bɛtɛ glycemic kɔntrol pan ɔl we dɛn de it ɛn ɛksesaiz ɛn dɛn nid fɔ de manej dɛn wet wan tɛm, Cagrilintide na fayn tritmɛnt opshɔn.
Kɔmbayn wit Ɔda Mɛrɛsin dɛn
Dɛn kin yuz cagrilintide togɛda wit difrɛn tradishɔnal antidiabetic drɔgs, lɛk metformin ɛn sulfonylureas. Kɔmbayn tɛrapi kin leva di sinajɛstik ifɛkt dɛm fɔ difrɛn drɔgs fɔ mɔ kɔmprɛhnsiv wan kɔntrol blɔd shuga ɛn wet. We dɛn yuz am togɛda wit mɛtfɔmin, di men tin we de mek di blɔd shuga go dɔŋ bay we i de mek di insulin nɔ de wok fayn ɛn i de ridyus di glukɔs we de kɔmɔt na di epatik, we di Kagrilintide de mek di blɔd shuga ɛn di wet go dɔŋ tru tin dɛn lɛk fɔ mek insulin kɔmɔt na di bɔdi ɛn fɔ mek pɔsin nɔ want fɔ it. di kכmbaynshכn fכ di tu kin kכntro di bכdi shuga lεvεl mכr fayn fayn wan pan T2D pasεnshכn dεm εn fכ impruv di wet stetכs mכr we i nכ de inkrεs di risk fכ advεs riakshכn lεk haypoglycemia.
5 Fɔ dɔn
Fɔ sɔmtin, Cagrilintide, as nyu drɔg fɔ trit tayp 2 dayabitis, de sho se i gɛt gud ɛfifikɛshɔn fɔ rigul di glukɔs na di blɔd ɛn fɔ manej di wet. Di we aw i de wok de mek i gɛt impɔtant aplikeshɔn valyu na T2D tritmɛnt, we de gi nyu tritmɛnt opshɔn fɔ di wan dɛn we gɛt tayp 2 dayabitis.
Sos dɛn we dɛn pul
[1] Abdulrahman A, Najjar S, Al-Zobaidy M. Efεkt dεm we liraglutide gεt pan weit kכntrכl εn blכd prεshכn na tayp 2 dayabεtis Ifekt dεm we liraglutide gεt pan weit kכntrכl εn blכd prεshכn pan tayp 2 dayabεtis mεllitus Irak pasεnshכn dεm[J]. J ɔ rnal ɔ f di Fakulti fɔ Mɛdisin, Bagdad, 2023,64:2022.DOI:10.32007/jfacmedbagdad.6441971.
[2] Kurtzhals P, Flindt Kreiner F, Singh Bindra R. Di rol we di wet kɔntrol de ple fɔ di mɛnejɛmɛnt fɔ tayp 2 dayabitis: Pɛspɛktiv pan sɛmaglutayd[J]. Dayabitis Risach ɛn Klinik Prɛktis, 2023,203.DOI:10.1016/j.diabres.2023.110881.
[3] Shalahuddin I, Maulana I, Pɛbrianti S, ɛn ɔda pipul dɛn. Blɔd Shuga Lɛvɛl Rɛgyuleshɔn insay Dayabitis Mɛlitus Tayp 2 Patiɛnt dɛn Tru Dayt Manejmɛnt[J]. Jurnal Aisyah : Jurnal Ilmu Kesehatan, 2022. Di wan dɛn we de stɔdi bɔt di Baybul.
[4] Mak Adam-Maks C, Geblɛr J. A., Bɛlɔs B. K., ɛn ɔda pipul dɛn. Kɔntempɔral mɛnejɛmɛnt fɔ pasɛnt dɛn we gɛt Tayp 2 dayabitis[J]. Ekspɛkt Rivyu fɔ Kardiovaskyuɛl Tɛrapi, 2010,8(6):767-770.DOI:10.1586/erc.10.62.
Prodak we de fɔ yuz fɔ risach nɔmɔ:
